Ubs Group Ag Halozyme Therapeutics, Inc. Call Options Transaction History

Ubs Group Ag

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2020 Jul 31, 2020	BUY	$16.25 - $26.81 $4.36 Million - $7.19 Million	268,100 Added 2708.08%	278,000 $7.45 Million
Q1 2020 May 01, 2020	SELL	$13.9 - $21.83 $1.1 Million - $1.72 Million	-78,900 Reduced 88.85%	9,900 $178,000
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $1.33 Million - $1.73 Million	88,800 New	88,800 $1.57 Million

442

122M

216K

140K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.18B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.